News

SB12 Equivalent to Soliris in Phase 1 Trial

Samsung Bioepis announced that its product SB12, a proposed biosimilar — a product that is highly similar, with no clinically meaningful differences, to an original patented product — to Soliris (eculizumab), showed equivalent properties with regards to the therapy’s safety, pharmacokinetics, and immune profile in a…

Plasma Exchange, Soliris May Help Treat Pregnancy-related aHUS

Plasma exchange and treatment with Soliris (eculizumab) may be used successfully to treat pregnancy-related atypical hemolytic uremic syndrome (aHUS) complicated by kidney failure, a case report suggests. The report, “Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review,” was published in…

Viper’s Bite Triggered aHUS, Case Report Says

A 57-year old man developed atypical hemolytic uremic syndrome (aHUS) after being bitten by a pit viper belonging to the Bothrops aspe species, a recent case report suggests. According to its authors, this is the first report describing an association between aHUS and this viper species, likely triggered by venom-induced…

Pregnancy Generally Safe for Women With aHUS, Study Suggests

If closely monitored, women with atypical hemolytic uremic syndrome (aHUS) can have successful and uncomplicated pregnancies, including those on dialysis or patients who had undergone a kidney transplant, according to a new study. Additionally, researchers confirmed that patients can safely and effectively be treated with Soliris (eculizumab), an…

Severe COVID-19 Suspected as Trigger of aHUS in 3-year-old Girl

COVID-19 appears to have triggered an exaggerated immune response in a toddler, leading to the development of atypical hemolytic uremic syndrome (aHUS) in the absence of disease-relevant mutations, scientists reported. “This is a rare case report of a child with COVID-19 developing HUS. Since HUS developed following a COVID-19…